Modified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasis

Surgery (United States)

Volumn 157, Issue 2, 2015, Pages 285-296

  Galizia, Gennaro ^a   Lieto, Eva ^a   De Vita, Ferdinando ^a   Castellano, Paolo ^a   Ferraraccio, Francesca ^a   Zamboli, Anna ^a   Mabilia, Andrea ^a   Auricchio, Annamaria ^a   De Sena, Gabriele ^a   De Stefano, Lorenzo ^a   Cardella, Francesca ^a   Barbarisi, Alfonso ^a   Orditura, Michele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MODIFIED D2 LYMPHADENECTOMY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPER HEPATIC ARTERY; RANDOMIZED CONTROLLED TRIAL; SPLENECTOMY; STANDARD D2 LYMPHADENECTOMY; STOMACH CARCINOMA; SURGICAL PATIENT; SURGICAL RISK; TOTAL STOMACH RESECTION; TUMOR RECURRENCE; ADENOCARCINOMA; ADVERSE EFFECTS; CANCER STAGING; GASTRECTOMY; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE COMPLICATIONS; PROCEDURES; PROPORTIONAL HAZARDS MODEL; SECONDARY; STOMACH NEOPLASMS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS;

EID: 84921433631     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2014.09.012     Document Type: Article

References (48)

1. A. Jemal, M.M. Center, C. DeSantis, and E.M. Ward Global patterns of cancer incidence and mortality rates and trends Cancer Epidemiol Biomarkers Prev 19 2010 1893 1907
2. D. Marrelli, A. De Stefano, G. de Manzoni, P. Morgagni, A. Di Leo, and F. Roviello Prediction of recurrence after radical surgery for gastric cancer: a scoring system obtained from a prospective multicenter study Ann Surg 241 2005 247 255
3. L. Ferri Extended lymphadenectomy in gastric cancer is crucial World J Surg 37 2013 1768 1772
4. M. Sasako, T. Sano, S. Yamamoto, Y. Kurokawa, A. Nashimoto, and A. Kurita D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer N Engl J Med 359 2008 453 462
5. Y.J. Bang, Y.W. Kim, H.K. Yang, H.C. Chung, Y.K. Park, and K.H. Lee Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial Lancet 379 2012 315 321
6. B. Schmidt, and S.S. Yoon D1 versus D2 lymphadenectomy for gastric cancer J Surg Oncol 107 2013 259 264
7. L. Jiang, K.H. Yang, Q.L. Guan, P. Zhao, Y. Chen, and J.H. Tian Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: a meta-analysis J Surg Oncol 107 2013 807 814
8. G.H. Kampschöer, K. Maruyama, C.J. van de Velde, M. Sasako, T. Kinoshita, and K. Okabayashi Computer analysis in making preoperative decisions: a rational approach to lymph node dissection in gastric cancer patients Br J Surg 76 1989 905 908
9. M. Nishi, Y. Omori, and K. Miwa Japanese classification of gastric carcinoma 1995 Kanehara & Co., Ltd Tokyo
10. M. Sasako, P. McCulloch, T. Kinoshita, and K. Maruyama New method to evaluate the therapeutic value of lymph node dissection for gastric cancer Br J Surg 82 1995 346 351
11. L.H. Sobin, M.K. Gospodarowicz, and C. Wittekind International Union Against Cancer (UICC) TNM classification of malignant tumors 7th ed. 2010 Wiley-Liss New York
12. T. Sano, and T. Aiko Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points Gastric Cancer 14 2011 97 100
13. Japanese Gastric Cancer Association Japanese gastric cancer treatment guidelines 2010 (ver. 3) Gastric Cancer 14 2011 101 123
14. S. Rausei, G. Dionigi, T. Sano, M. Sasako, A. Biondi, and P. Morgagni Updates on surgical management of advanced gastric cancer: new evidence and trends. Insights from the First International Course on Upper Gastrointestinal Surgery- Varese (Italy), December 2, 2011 Ann Surg Oncol 20 2013 3942 3947
15. J. Lee, H. Lim do, S. Kim, S.H. Park, J.O. Park, and Y.S. Park Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial J Clin Oncol 30 2012 268 273
16. J.J. Bonenkamp, J. Hermans, M. Sasako, C.J. van de Velde, K. Welvaart, and I. Songun Extended lymph-node dissection for gastric cancer N Engl J Med 340 1999 908 914
17. A. Cuschieri, S. Weeden, J. Fielding, J. Bancewicz, J. Craven, and V. Joypaul Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group Br J Cancer 79 1999 1522 1530
18. V.E. Strong, and S.S. Yoon Extended lymphadenectomy in gastric cancer is debatable World J Surg 37 2013 1773 1777
19. M. Degiuli, M. Sasako, A. Ponti, A. Vendrame, M. Tomatis, and C. Mazza Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer Br J Surg 101 2014 23 31
20. J.H. Lee, K.W. Ryu, J.H. Lee, S.R. Park, C.G. Kim, and M.C. Kook Learning curve for total gastrectomy with D2 lymph node dissection: cumulative sum analysis for qualified surgery Ann Surg Oncol 13 2006 1175 1181
21. H.H. Hartgrink, C.J. van de Velde, H. Putter, J.J. Bonenkamp, E. Klein Kranenbarg, and I. Songun Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial J Clin Oncol 22 2004 2069 2077
22. I. Songun, H. Putter, E.M. Kranenbarg, M. Sasako, and C.J. van de Velde Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial Lancet Oncol 11 2010 439 449
23. T. Sano, M. Sasako, S. Yamamoto, A. Nashimoto, A. Kurita, and M. Hiratsuka Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501 J Clin Oncol 22 2004 2767 2773
24. M. Degiuli, M. Sasako, A. Ponti Italian Gastric Cancer Study Group Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer Br J Surg 97 2010 643 649
25. T. Sano, M. Sasako, T. Shibata, S. Yamamoto, A. Tsuburaya, and A. Nashimoto Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma (JCOG0110): analyses of operative morbidity, operation time, and blood loss J Clin Oncol 28 15 Suppl 2010 4020 (ASCO meeting abstract)
26. S. Erturk, Y. Ersan, Y. Cicek, G. Dogusoy, and M. Senocak Effect of simultaneous splenectomy on the survival of patients undergoing curative gastrectomy for proximal gastric carcinoma Surg Today 33 2003 254 258
27. W. Yu, G.S. Choi, and H.Y. Chung Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer Br J Surg 93 2006 559 563
28. S.S. Brar, R. Seevaratnam, R. Cardoso, C. Law, L. Helyer, and N. Coburn A systematic review of spleen and pancreas preservation in extended lymphadenectomy for gastric cancer Gastric Cancer 15 Suppl 1 2012 S89 S99
29. A. Cuschieri, P. Fayers, J. Fielding, J. Craven, J. Bancewicz, and V. Joypaul Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group Lancet 347 1996 995 999
30. H. Goto, M. Tokunaga, N. Sugisawa, Y. Tanizawa, E. Bando, and T. Kawamura Value of splenectomy in patients with Siewert type II adenocarcinoma of the esophagogastric junction Gastric Cancer 16 2013 590 595
31. P.A. Clavien, J. Barkun, M.L. de Oliveira, J.N. Vauthey, D. Dindo, and R.D. Schulick The Clavien-Dindo classification of surgical complications: five-year experience Ann Surg 250 2009 187 196
32. K. Oba, X. Paoletti, S. Alberts, Y.J. Bang, J. Benedetti, and H. Bleiberg Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis J Natl Cancer Inst 105 2013 1600 1607
33. K.M. Reid-Lombardo, G. Gay, L. Patel-Parekh, J.A. Ajani, J.H. Donohue Gastric Patient Care Evaluation Group from the Commission on Cancer Treatment of gastric adenocarcinoma may differ among hospital types in the United States, a report from the National Cancer Data Base J Gastrointest Surg 11 2007 410 419
34. J. Wang, P. Dang, C.P. Raut, P.K. Pandalai, U.N. Maduekwe, and D.W. Rattner Comparison of a lymph node ratio-based staging system with the 7th AJCC system for gastric cancer: analysis of 18,043 patients from the SEER database Ann Surg 255 2012 478 485
35. M.A. Memon, M.S. Subramanya, S. Khan, M.B. Hossain, E. Osland, and B. Memon Meta-analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma Ann Surg 253 2011 900 911
36. B. Schmidt, K.K. Chang, U.N. Maduekwe, N. Look-Hong, D.W. Rattner, and G.Y. Lauwers D2 lymphadenectomy with surgical ex vivo dissection into node stations for gastric adenocarcinoma can be performed safely in Western patients and ensures optimal staging Ann Surg Oncol 20 2013 2991 2999
37. J.S. Macdonald, S.R. Smalley, J. Benedetti, S.A. Hundahl, N.C. Estes, and G.N. Stemmermann Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction N Engl J Med 345 2001 725 730
38. M. D'Angelica, M. Gonen, M.F. Brennan, A.D. Turnbull, M. Bains, and M.S. Karpeh Patterns of initial recurrence in completely resected gastric adenocarcinoma Ann Surg 240 2004 808 816
39. S. Sakuramoto, M. Sasako, T. Yamaguchi, T. Kinoshita, M. Fujii, and A. Nashimoto Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 2007 1810 1820
40. H.S. Ahn, H.J. Lee, M.W. Yoo, S.H. Jeong, D.J. Park, and H.H. Kim Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period Br J Surg 98 2011 255 260
41. C.W. Wu, C.A. Hsiung, S.S. Lo, M.C. Hsieh, J.H. Chen, and A.F. Li Nodal dissection for patients with gastric cancer: a randomised controlled trial Lancet Oncol 7 2006 309 315
42. H. Ito, H. Inoue, N. Odaka, H. Satodate, S. Mukai, and T. Omoto Prognostic impact of prophylactic splenectomy for upper-third gastric cancer: a cohort study Anticancer Res 33 2013 277 282
43. S. Nunobe, S. Ohyama, H. Sonoo, N. Hiki, T. Fukunaga, and Y. Seto Benefit of mediastinal and para-aortic lymph-node dissection for advanced gastric cancer with esophageal invasion J Surg Oncol 97 2008 392 395
44. D.Y. Oh, and Y.J. Bang Adjuvant and neoadjuvant therapy for gastric cancer Curr Treat Options Oncol 14 2013 311 320
45. J.L. Dikken, J.W. van Sandick, H.A. Maurits Swellengrebel, P.A. Lind, H. Putter, and E.P. Jansen Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS) BMC Cancer 11 2011 329
46. A. Donner Approaches to sample size estimation in the design of clinical trials - a review Stat Med 3 1984 199 214
47. S.A. Cannistra Phase II trial in Journal of Clinical Oncology J Clin Oncol 27 2009 3073 3076
48. T. Sano, S. Yamamoto, M. Sasako Japan Clinical Oncology Group Study LCOG 0110-MF Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF Jpn J Clin Oncol 32 2002 363 364